ACR

Study Shows Denosumab Has Greater Impact on Bone Mineral Density Than Alendronate

January 14, 2021

The increase in spinal bone mineral density was significantly higher in patients treated with denosumab compared with alendronate after adjustment for bone mineral density at baseline, age, sex, and other osteoporosis risk factors.

Reducing the Immunogenicity of Pegloticase in Patients With Refractory Gout

December 21, 2020

Puja Khanna MD, MPH, associate professor of medicine at the University of Michigan, discusses a presentation she gave at the American College of Rheumatology Convergence 2020 on reducing the immunogenicity of pegloticase and improving its efficacy.

SPIRIT-H2H: Ixekizumab as Efficacious as Adalimumab for Psoriatic Arthritis

December 16, 2020

Ixekizumab appears to provide significantly greater simultaneous joint and skin improvement for patients with psoriatic arthritis than adalimumab and doesn’t require combination with methotrexate to boost its efficacy.

Patient Perspectives in Lupus

December 04, 2020

In today's interview, our focus is on patient perspectives. During the American College of Rheumatology annual meeting last month, Juana Mata shared her story of a life living with lupus. Getting an accurate diagnosis wasn't easy, but eventually she found a doctor and treatment that's working for her. In today's interview, Kim Gorgens, a psychologist and Rheumatology Network board member interviews Juana and her sister, Estela, who describe turning a lupus diagnosis into a positive force for change through advocacy. The sisters have created a non-profit group called Looms for Lupus in which they embrace art therapy to relieve stress.

New Year May Bring New Lupus Treatments

November 13, 2020

At this year's annual meeting of the American College of Rheumatology, there were a number of studies presented on different treatments for lupus. It's an exciting time in lupus research says Dr. Richard Furie, chief of rheumatology at Northwell Health in New York. In today's one on one interview, he breaks down some of the lupus studies presented at the meeting

ACR Set to Issue Updated Treatment Guidelines

November 12, 2020

The American College of Rheumatology is expected to issue updated treatment guidelines for rheumatoid arthritis no later than spring 2021. The new guidelines will include recommended uses for biologics approved since the last update in 2015―including JAK inhibitors.

ACR Conference Roundup: New RA Treatment Guidelines Preview

November 12, 2020

In this week's news roundup from Rheumatology Network, we highlight studies presented at the annual meeting of the American College of Rheumatology, which wrapped this week. Among the stories we covered included a preview of the soon-to-be released rheumatoid arthritis guidelines, promising new treatments for lupus nephritis and advances in osteoporosis care. Learn more in today's news roundup.

Q&A: Do glucocorticoids have a positive impact on bone?

November 12, 2020

In this Q&A, Edgar Wiebe, M.D., of Charité University Medicine Berlin, discusses the findings of a study recently presented at the American College of Rheumatology annual meeting that looked at the impact of a number of factors on bone mineral density.

Medication Management Preferences Depend on Case Burden

November 12, 2020

A survey of rheumatologists in the United States found that their prescriptions of medications such as NSAIDs, biologics and steroids during the COVID-19 pandemic is based on regional case burden rather than American College of Rheumatology guidance.

Q&A: Methotrexate and Tuberculosis

November 12, 2020

Tuberculosis screening and ongoing clinical care is needed for patients prescribed methotrexate, particularly if co-administered with corticosteroids or other immunosuppressants, who live in areas where tuberculosis is common, according to researchers recently reporting at the annual meeting of the American College of Rheumatology.

In systemic sclerosis, which factors are linked to an increased risk of osteoporosis and fracture?

November 11, 2020

Several factors can increase the risk of fractures and osteoporosis in patients with systemic sclerosis, including poor functional status and being underweight, according to researchers reporting at the annual meeting of the American College of Rheumatology on Saturday. However, the impact of proton pump inhibitors was less clear.

Tofacitinib, Adalimumab, Methotrexate Show Similar Influenza Adverse Events in RA

November 10, 2020

In a study that examined the influenza adverse events (AEs) of tofacitinib (Xeljanz, Pfizer) in patients with rheumatoid arthritis, similar AEs were seen with tofacitinib, adalimumab, methotrexate, and placebo, and between different tofacitinib doses and patient age groups, according to researchers reporting at the annual meeting of the American College of Rheumatology on Monday.

Q&A: Hydroxychloroquine and Heart Rhythm in SLE

November 10, 2020

Patients with systemic lupus erythematous (SLE) who take hydroxychloroquine do not have any differences in their corrected QT (QTc) intervals on electrocardiogram (EKG), even if they have chronic kidney disease (CKD), according to researchers reporting at the annual meeting of the American College of Rheumatology on Monday.

Rheumatic Disease Patients Bear the Brunt of Antimalarial Shortages

November 10, 2020

Lessons learned from antimalarial drug shortages during the COVID-19 pandemic: rheumatic disease patients in African and South-East Asia had difficulty obtaining antimalarials as compared to counterparts in the Americas and Europe. Shortages led to worse mental and physical health outcomes. Antimalarials did not protect patients from COVID-19.